The global plant sources anti cancer agents market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of cancer and rising awareness about the benefits of plant-based medicines. The major factors driving this market are increasing prevalence of cancer, rising awareness about the benefits of plant-based medicines, and growing demand for natural products. However, high cost associated with these drugs may hamper the growth rate in some regions such as North America and Europe.
The global plant sources anti cancer agents market by type includes paclitaxel (12%), vinorelbine (11%), irinotecan (10%), hydroxycamptothecin (8%), docetaxel (7%). The application segment includes ovarian cancer (14%), cervical cancer (13%), breast cancer(12%).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of cancer globally is one of the major factors driving the growth of this market.
- Increasing awareness about plant sources anti-cancer agents among consumers and healthcare professionals is also driving the growth of this market.
- The increasing number of research and development activities in this field are also contributing to the growth of this market.
- Lack of awareness about plant sources anti-cancer agents among consumers and healthcare professionals, high cost associated with these products, lack or insufficient distribution channels are some factors that may hamper the growth rate.
Industry Growth Insights published a new data on “Plant Sources Anti Cancer Agents Market”. The research report is titled “Plant Sources Anti Cancer Agents Market research by Types (Paclitaxel, Vinorelbine, Irinotecan, Hydroxycamptothecin, Docetaxel, Other), By Applications (Ovarian Cancer, Cervical Cancer, Breast Cancer, Other), By Players/Companies Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology, West-Ward Pharmaceuticals, Pfizer, Actiza Pharmaceutical, Getwell, Taj Pharma, Cipla, Salius”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Plant Sources Anti Cancer Agents Market Research Report
By Type
Paclitaxel, Vinorelbine, Irinotecan, Hydroxycamptothecin, Docetaxel, Other
By Application
Ovarian Cancer, Cervical Cancer, Breast Cancer, Other
By Companies
Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology, West-Ward Pharmaceuticals, Pfizer, Actiza Pharmaceutical, Getwell, Taj Pharma, Cipla, Salius
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Plant Sources Anti Cancer Agents Market Report Segments:
The global Plant Sources Anti Cancer Agents market is segmented on the basis of:
Types
Paclitaxel, Vinorelbine, Irinotecan, Hydroxycamptothecin, Docetaxel, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Cervical Cancer, Breast Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Phyton
- ScinoPharm
- Novasep
- Samyang
- Polymed
- TAPI (Teva)
- Fresenius-kabi
- Huiang biopharma
- Southpharma
- Yunnan Hande
- Hainan Yew Pharm
- Jiangsu Yew Biotechnology
- West-Ward Pharmaceuticals
- Pfizer
- Actiza Pharmaceutical
- Getwell
- Taj Pharma
- Cipla
- Salius
Highlights of The Plant Sources Anti Cancer Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Paclitaxel
- Vinorelbine
- Irinotecan
- Hydroxycamptothecin
- Docetaxel
- Other
- By Application:
- Ovarian Cancer
- Cervical Cancer
- Breast Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plant Sources Anti Cancer Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plant Sources Anti Cancer Agents are substances found in plants that have the ability to inhibit or stop the growth of cancer cells. Some plant sources of anti-cancer agents include:nnCannabis sativa u2013 This plant contains cannabinoids, which are chemicals that can block cell growth and cause cancer cells to die. Cannabis sativa is also a natural source of antioxidants, which can help protect against damage caused by free radicals.nnu2013 This plant contains cannabinoids, which are chemicals that can block cell growth and cause cancer cells to die. Cannabis sativa is also a natural source of antioxidants, which can help protect against damage caused by free radicals. Curcumin u2013 Curcumin is an extract from the turmeric root used in many Indian dishes and as a dietary supplement for its anti-inflammatory properties. Studies have shown that curcumin has strong anticancer effects when it comes to both leukemia and colon cancer cells in vitro (in test tubes). However, more research needs to be done before we know if curcumin actually helps people with these diseases live longer overall.
Some of the major companies in the plant sources anti cancer agents market are Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology, West-Ward Pharmaceuticals, Pfizer, Actiza Pharmaceutical, Getwell, Taj Pharma, Cipla, Salius.
The plant sources anti cancer agents market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Plant Sources Anti Cancer Agents Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Plant Sources Anti Cancer Agents Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Plant Sources Anti Cancer Agents Market - Supply Chain
4.5. Global Plant Sources Anti Cancer Agents Market Forecast
4.5.1. Plant Sources Anti Cancer Agents Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Plant Sources Anti Cancer Agents Market Size (000 Units) and Y-o-Y Growth
4.5.3. Plant Sources Anti Cancer Agents Market Absolute $ Opportunity
5. Global Plant Sources Anti Cancer Agents Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Type
5.3.1. Paclitaxel
5.3.2. Vinorelbine
5.3.3. Irinotecan
5.3.4. Hydroxycamptothecin
5.3.5. Docetaxel
5.3.6. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Plant Sources Anti Cancer Agents Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Application
6.3.1. Ovarian Cancer
6.3.2. Cervical Cancer
6.3.3. Breast Cancer
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Plant Sources Anti Cancer Agents Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Plant Sources Anti Cancer Agents Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Plant Sources Anti Cancer Agents Demand Share Forecast, 2019-2026
9. North America Plant Sources Anti Cancer Agents Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Application
9.4.1. Ovarian Cancer
9.4.2. Cervical Cancer
9.4.3. Breast Cancer
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Type
9.7.1. Paclitaxel
9.7.2. Vinorelbine
9.7.3. Irinotecan
9.7.4. Hydroxycamptothecin
9.7.5. Docetaxel
9.7.6. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Plant Sources Anti Cancer Agents Demand Share Forecast, 2019-2026
10. Latin America Plant Sources Anti Cancer Agents Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Application
10.4.1. Ovarian Cancer
10.4.2. Cervical Cancer
10.4.3. Breast Cancer
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Type
10.7.1. Paclitaxel
10.7.2. Vinorelbine
10.7.3. Irinotecan
10.7.4. Hydroxycamptothecin
10.7.5. Docetaxel
10.7.6. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Plant Sources Anti Cancer Agents Demand Share Forecast, 2019-2026
11. Europe Plant Sources Anti Cancer Agents Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Application
11.4.1. Ovarian Cancer
11.4.2. Cervical Cancer
11.4.3. Breast Cancer
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Type
11.7.1. Paclitaxel
11.7.2. Vinorelbine
11.7.3. Irinotecan
11.7.4. Hydroxycamptothecin
11.7.5. Docetaxel
11.7.6. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Plant Sources Anti Cancer Agents Demand Share, 2019-2026
12. Asia Pacific Plant Sources Anti Cancer Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Application
12.4.1. Ovarian Cancer
12.4.2. Cervical Cancer
12.4.3. Breast Cancer
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Type
12.7.1. Paclitaxel
12.7.2. Vinorelbine
12.7.3. Irinotecan
12.7.4. Hydroxycamptothecin
12.7.5. Docetaxel
12.7.6. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Plant Sources Anti Cancer Agents Demand Share, 2019-2026
13. Middle East & Africa Plant Sources Anti Cancer Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Application
13.4.1. Ovarian Cancer
13.4.2. Cervical Cancer
13.4.3. Breast Cancer
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Plant Sources Anti Cancer Agents Market Size and Volume Forecast by Type
13.7.1. Paclitaxel
13.7.2. Vinorelbine
13.7.3. Irinotecan
13.7.4. Hydroxycamptothecin
13.7.5. Docetaxel
13.7.6. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Plant Sources Anti Cancer Agents Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Plant Sources Anti Cancer Agents Market: Market Share Analysis
14.2. Plant Sources Anti Cancer Agents Distributors and Customers
14.3. Plant Sources Anti Cancer Agents Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Phyton
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. ScinoPharm
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novasep
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Samyang
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Polymed
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. TAPI (Teva)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Fresenius-kabi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Huiang biopharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Southpharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Yunnan Hande
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hainan Yew Pharm
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Jiangsu Yew Biotechnology
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. West-Ward Pharmaceuticals
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Pfizer
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Actiza Pharmaceutical
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Getwell
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Taj Pharma
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Cipla
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Salius
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
